ProCE Banner Activity

Insights on New Data With BTK Inhibitors for CLL and MCL From the SOHO 2022 Annual Meeting

Conference Coverage
Clinical Thought
In this commentary, 2 experts discuss the implications of clinical trial data presented at the SOHO 2022 Annual Meeting on BTK inhibitor–based treatments for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Released: November 16, 2022

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Kami Maddocks

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Christopher R. Flowers, MD, MS: consulting/advisory/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; research funding (institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, MorphoSys, Pharmacyclics.